Replies to post #9642 on Arch Therapeutics Inc (ARTH)

[Polyphemus]

ARTH has obtained a marketing clearance for AC5 as a topical wound dressing. It is legally allowed to call AC5 a hemostat, but it will compete in the very crowded wound dressing space that is price sensitive, particularly in Europe, regardless of how it is branded.

ARTH has had marketing clearance for AC5 in the US for more than 17 months & has done nothing with it. US is the larger & more profitable market, so why no commercialization if the product is impactful in the market? Why no announcement of a distribution agreement for any market? More recent FDA 501(k) was for a manufacturing change, which is not a big deal, despite claims on this board to the contrary.

Obtaining 510(k) and CE mark for a Class II wound dressing will not be the precipitating events for an acquisition. Market performance of the product could be, esp. if the product is seriously differentiated on a clinical basis.

Let's see ARTH's announcement about commercialization partners and plans. Note that ARTH still has no senior marketing person listed as an executive manager. Time for some meat on the table.

[mustangpower]

It at least stops the bleeding and reaffirms that Norchi and his team are putting everything they have into making this a real company that can actually produce revenue and profits in the future.

No pun intended